Tapentadol is partially metabolized because of the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with medication that boost or repress the action/expression of a number of of such enzymes, in addition to with substrates of these enzymes (resulting from Competitors to the enzyme); some enzyme mediators/substrates demand